ASSOCIATIONS WITH CONTRALATERAL RECURRENCE FOLLOWING NEPHRECTOMY FOR RENAL CELL CARCINOMA USING A COHORT OF 2,352 PATIENTS
Abstract
Purpose:
We determined the incidence of and factors associated with the development of renal cell carcinoma (RCC) in the contralateral kidney after nephrectomy for localized RCC.
Materials and Methods:
Between 1970 and 2000, 2,352 patients with sporadic, localized unilateral RCC and a normal contralateral kidney underwent nephrectomy for RCC. Cancer specific survival rates were estimated using the Kaplan-Meier method. Univariate Cox proportional hazards models were used to determine associations with outcome.
Results:
Of the 2,352 patients studied 28 (1.2%) had RCC in the contralateral kidney, including 20 with clear cell and 8 with papillary RCC. Mean time from primary surgery to contralateral recurrence was 5.2 years (median 4.8, range 0 to 18) for clear cell RCC compared with 5.6 years (median 1.3, range 0 to 21) for papillary cell RCC. Positive surgical margins (risk ratio 14.23, p = 0.010) and multifocality (risk ratio 5.74, p = 0.019) were significantly associated with contralateral recurrence following nephrectomy for clear cell RCC, while nuclear grade (risk ratio for grades 3/4 vs 1/2, 4.78, p = 0.040) was significantly associated with contralateral recurrence following nephrectomy for papillary RCC. In patients with clear cell RCC estimated cancer specific survival rates 1, 3, and 5 years following contralateral recurrence were 93.8%, 80.2% and 72.9%, respectively.
Conclusions:
In patients with localized RCC and a normal contralateral kidney who underwent nephrectomy for RCC positive surgical margins and multifocality were significant predictors of contralateral recurrence for clear cell RCC, while nuclear grade was a significant predictor of contralateral recurrence for papillary RCC.
References
- 1 : The results of radical nephrectomy for renal cell carcinoma. J Urol1969; 101: 297. Link, Google Scholar
- 2 : Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol1999; 162: 1930. Link, Google Scholar
- 3 : Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol2000; 163: 442. Link, Google Scholar
- 4 : Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol2000; 163: 730. Link, Google Scholar
- 5 : Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc2000; 75: 1236. Google Scholar
- 6 : Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol2002; 167: 884. Link, Google Scholar
- 7 : Bilateral asynchronous renal cell carcinoma. Computed tomography of the contralateral kidney 10–43 years after nephrectomy. Eur Urol1992; 22: 209. Google Scholar
- 8 : Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. J Clin Oncol2002; 20: 2370. Google Scholar
- 9 : Bilateral non-familial renal cell carcinoma. Ann Surg Oncol1998; 5: 548. Google Scholar
- 10 : Nephron-preserving surgery for unilateral renal cell carcinoma: which pathologic variables contribute to contralateral renal tumor recurrence?. J Urol1998; 159: 169. abstract 648. Google Scholar
- 11 : Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer1997; 80: 987. Google Scholar
- 12 : The Heidelberg classification of renal cell tumours. J Pathol1997; 183: 131. Google Scholar
- 13 : Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol2002; 118: 877. Google Scholar
- 14 : The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol2003; 169: 1276. Link, Google Scholar
From the Departments of Urology (AHB-H, BCL, HZ, MLB), Laboratory Medicine and Pathology (JCC) and Biostatistics (CML), Mayo Clinic, Rochester, Minnesota
